GLABF (Gemina Laboratories) Cash Conversion Cycle: 0.00 (As of Oct. 2025)


What is Gemina Laboratories Cash Conversion Cycle?

Gemina Laboratories GLABF -27.59% Cash Conversion Cycle is 0.00 as of Oct. 2025. The stock has 2 warning signs investors should review.

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Gemina Laboratories's Days Sales Outstanding for the three months ended in Oct. 2025 was 0.
Gemina Laboratories's Days Inventory for the three months ended in Oct. 2025 was .
Gemina Laboratories's Days Payable for the three months ended in Oct. 2025 was .
Therefore, Gemina Laboratories's Cash Conversion Cycle (CCC) for the three months ended in Oct. 2025 was 0.00.

Gemina Laboratories  (OTCPK:GLABF) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.

Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.

Gemina Laboratories Cash Conversion Cycle Related Terms

Gemina Laboratories Cash Conversion Cycle Historical Data

* Premium members only.

The historical data trend for Gemina Laboratories's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gemina Laboratories Cash Conversion Cycle Chart

Gemina Laboratories Annual Data
Trend Jan21 Jan22 Jan23 Jan24 Jan25
Cash Conversion Cycle
0.00 0.00 0.00 0.00 0.00

Gemina Laboratories Quarterly Data
Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

GLABF vs VRTX, REGN, ALNY: Cash Conversion Cycle Comparison

For the Biotechnology subindustry, Gemina Laboratories's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gemina Laboratories Cash Conversion Cycle vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gemina Laboratories's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Gemina Laboratories's Cash Conversion Cycle falls into.


Gemina Laboratories Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Gemina Laboratories's Cash Conversion Cycle for the fiscal year that ended in Jan. 2025 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=+-
=0.00

Gemina Laboratories's Cash Conversion Cycle for the quarter that ended in Oct. 2025 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=0+-
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash Conversion Cycle →
What does a Cash Conversion Cycle of 0.00 mean?
Gemina Laboratories (GLABF) has a Cash Conversion Cycle of 0.00 as of Oct. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Gemina Laboratories and its competitors.
Is Gemina Laboratories' Cash Conversion Cycle too high?
Gemina Laboratories' current Cash Conversion Cycle is 0.00.
How does Gemina Laboratories' Cash Conversion Cycle compare to VRTX and REGN?
Gemina Laboratories' Cash Conversion Cycle of 0.00 can be compared against companies in the Biotechnology industry. The industry median Cash Conversion Cycle is 102.42. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Biotechnology company?
The median Cash Conversion Cycle among Biotechnology companies is 102.42, based on 874 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Gemina Laboratories and its competitors. For the Biotechnology industry, the median Cash Conversion Cycle is 102.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gemina Laboratories's current Cash Conversion Cycle is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gemina Laboratories stock overvalued right now?
Gemina Laboratories (GLABF) has a current Cash Conversion Cycle of 0.00. The current Cash Conversion Cycle is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Gemina Laboratories (GLABF), the current Cash Conversion Cycle is 0.00 as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gemina Laboratories Business Description

Address 3600 Gilmore Mall, Suite 302, Burnaby, BC, CAN, V5G 4R8
Gemina Laboratories Ltd is a biotechnology company that operates in the In Vitro Diagnostics (IVD) and human wellness monitoring market under the name Gemina Labs. The company endeavors to develop novel surface functionalization chemistries for the detection of pathogens and biomarkers.